You are here: Industry Insights > trial

News List

InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S. July 24, 2024
Beijing, July 24, 2024 – InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases
Dermaliq Therapeutics Announces Positive Topline Results from Phase 1b/2a Trial Evaluating the Safety and Efficacy of DLQ01 for the Treatment of Androgenetic Alopecia (AGA) in Men Biotech Newswire
July 17, 2024
DLQ01 is potentially the first new topical treatment option for both men and women suffering from AGA in a very long time.
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA PharmaSources
June 11, 2024
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) ap
New CRO Focused on Cannabis-based Drug Trials Launched PharmaSources
May 23, 2024
Cannovation Clinical Research Partners takes a holistic approach to assist businesses throughout the entire product lifecycle, encompassing product development, commercialization, and launch phases.
InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma PharmaSources
May 21, 2024
The first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therapy for chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL) in China.
InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis PharmaSources
May 16, 2024
InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
Decentralising research: Virtual clinical trials Suzanne Elvidge
May 14, 2024
Clinical trials are vital as the basis of developing safe and effective drugs, but they can be slow and expensive.
Clinical Research Organization's (CROs) using Artificial Intelligence (AI) tools in restructuring the clinical trials Shruti Talashi
April 11, 2024
Healthcare is embracing AI for better diagnosis, drug development, and patient care.
Toxys Reports Positive Results from the OECD Ring Trial Validation of ToxTracker in a Peer-Reviewed Article PharmaSources
April 10, 2024
Toxys announces the peer-reviewed publication of the positive results from an international interlaboratory validation of ToxTracker©.
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma in China Chunhua Lu
March 13, 2024
BTK inhibitor orelabrutinib as first-line therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China.